DRNA - Dicerna Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.70
+0.10 (+0.79%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.60
Open12.52
Bid9.10 x 900
Ask0.00 x 1000
Day's Range12.31 - 12.74
52 Week Range2.69 - 15.80
Volume177,867
Avg. Volume679,163
Market Cap670.834M
Beta3.02
PE Ratio (TTM)N/A
EPS (TTM)-2.75
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
Trade prices are not sourced from all markets
  • Business Wire9 days ago

    Dicerna Receives Recommendation from EMA Committee to Designate DCR-PHXC an Orphan Medicinal Product for the Treatment of Primary Hyperoxaluria (PH) in the EU

    Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has recommended designating DCR-PHXC, the Company’s lead GalXC™ product candidate, as an orphan medicinal product for the treatment of primary hyperoxaluria (PH) in the European Union (EU). The European Commission (EC) is expected to review the COMP opinion and issue a final ruling within 30 days of receipt. Separately, Dicerna recently announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to DCR-PHXC for the treatment of PH.

  • Business Wirelast month

    Dicerna Set to Join the Russell 3000® and Russell 2000® Indexes

    Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opens on June 25, according to a preliminary list of additions posted ...

  • ACCESSWIRElast month

    Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on DERM sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Daré Bioscience Inc. (NASDAQ: DARE), Dermira Inc. (NASDAQ: DERM), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), and Egalet Corp. (NASDAQ: EGLT).

  • Business Wire2 months ago

    Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial

    Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company has dosed the first primary hyperoxaluria (PH) patient with DCR-PHXC in the Group B portion of the PHYOX Phase 1 clinical trial. DCR-PHXC is an investigational GalXC™ product candidate in development for the treatment of all forms of PH, a family of severe, rare, inherited disorders of the liver that often result in kidney failure. The Company also announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to DCR-PHXC for the treatment of PH on May 15, 2018.

  • Business Wire2 months ago

    Dicerna to Present at the Jefferies 2018 Global Healthcare Conference

    Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will provide a corporate update at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 2:30 p.m.

  • ACCESSWIRE2 months ago

    Wired News – Omeros Settles Lawsuit Against Lupin for Filing ANDA With FDA for Marketing Generic Version of OMIDRIA(R)

    LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Omeros Corp. (NASDAQ: OMER), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OMER as the Company's latest news hit the wire. On May 24, 2018, the Company announced that it has reached a settlement agreement with Lupin Ltd and its subsidiary Lupin Pharmaceuticals, Inc. ("Lupin") to resolve the patent infringement lawsuit filed against Lupin. Omeros had filed the case against Lupin as it had filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for approval to market a generic version of Omeros' commercial drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3%.

  • GlobeNewswire2 months ago

    Research Report Identifies Carolina Financial, Dicerna Pharmaceuticals, On Assignment, Digimarc, CIRCOR International, and Nordson with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, May 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Carolina ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of DRNA earnings conference call or presentation 14-May-18 8:30pm GMT

    Q1 2018 Dicerna Pharmaceuticals Inc Earnings Call

  • Associated Press2 months ago

    Dicerna Pharmaceuticals: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 30 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Business Wire2 months ago

    Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update

    Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today reported financial and operating results for the first quarter ended March 31, 2018.

  • ACCESSWIRE2 months ago

    Dicerna Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 4:30 PM Eastern ...

  • Where Dicerna Pharmaceuticals Inc’s (NASDAQ:DRNA) Earnings Growth Stands Against Its Industry
    Simply Wall St.2 months ago

    Where Dicerna Pharmaceuticals Inc’s (NASDAQ:DRNA) Earnings Growth Stands Against Its Industry

    Assessing Dicerna Pharmaceuticals Inc’s (NASDAQ:DRNA) past track record of performance is a useful exercise for investors. It allows us to understand whether the company has met or exceed expectations, whichRead More...

  • Business Wire2 months ago

    Dicerna to Report First Quarter 2018 Financial Results and Host Conference Call on May 14, 2018

    Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2018 financial results after market close on Monday, May 14, 2018. Management will host a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live via the Internet and will be available on the “Investors & Media” section of the Dicerna website, www.dicerna.com.

  • Dicerna Pharmaceuticals Settles All Litigation with Alnylam
    Market Realist3 months ago

    Dicerna Pharmaceuticals Settles All Litigation with Alnylam

    On April 20, Dicerna Pharmaceuticals (DRNA) announced that it had resolved all litigation with Alnylam Pharmaceuticals (ALNY). The settlement allows Dicerna to advance all its key and planned pipeline programs while simultaneously maintaining a strong balance sheet. Under the terms of the agreement, Alnylam will dismiss all claims of trade secret misappropriation and other related claims brought in Massachusetts against Dicerna Pharmaceuticals.

  • Motley Fool3 months ago

    Why Dicerna Rocketed Higher Today

    Investors are happy the biotech ended a lawsuit hanging over its head.

  • Dicerna to pay $27M to settle Alnylam trade secrets lawsuit
    American City Business Journals3 months ago

    Dicerna to pay $27M to settle Alnylam trade secrets lawsuit

    The Cambridge biotechs are both developing RNA interference drugs, which are designed to silence disease-causing genes.

  • Reuters3 months ago

    U.S. biotech companies Alnylam, Dicerna settle trade secrets case

    Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015. Under the agreement, Dicerna said it will pay Alnylam $2 million up-front plus 983,208 shares of its common stock.

  • Reuters3 months ago

    U.S. biotech companies Alnylam, Dicerna settle trade secrets case

    Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015. Under the agreement, Dicerna said it will pay Alnylam $2 million up-front plus 983,208 shares of its common stock.

  • Business Wire3 months ago

    Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam

    Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that the company has resolved all litigation with Alnylam Pharmaceuticals, Inc.

  • Business Wire4 months ago

    Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference

    Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will provide a corporate update at the H.C.

  • Benzinga4 months ago

    Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation

    Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ), a biotechnology company developing GalXC RNAi platforms for various diseases, has seen its stock soar 140 percent over the past six months. But a combination ...

  • ACCESSWIRE4 months ago

    Wired News – Alnylam Retains Global Rights for its Investigational RNAi Therapeutic Lumasiran

    Stock Monitor: Dicerna Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 14, 2018 / Active-Investors.com has just released a free research report on Alnylam Pharma, Inc. (NASDAQ: ALNY ). If ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of DRNA earnings conference call or presentation 8-Mar-18 9:30pm GMT

    Q4 2017 Dicerna Pharmaceuticals Inc Earnings Call

  • Benzinga4 months ago

    Chardan: After Dicerna Pharma's 370% Run, Wait For Better Entry Point

    Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) could become a player in the emerging field of small RNA interference, or RNAi, according to Chardan Capital Markets.  The Analyst Chardan analyst Keay Nakae ...